Wells Fargo & Company Biogen Inc. Call Options Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $1.05 Million - $1.2 Million	4,100 New	4,100 $1.14 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $11.2 Million - $15.5 Million	57,600 Added 576.0%	67,600 $18 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $387,540 - $488,280	2,000 Added 25.0%	10,000 $2.11 Million
Q1 2021 May 13, 2021	BUY	$242.95 - $284.63 $728,850 - $853,890	3,000 Added 60.0%	8,000 $2.24 Million
Q4 2020 Feb 09, 2021	BUY	$236.26 - $355.63 $1.18 Million - $1.78 Million	5,000 New	5,000 $69,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.